NRX Pharmaceuticals Inc

:NRXP   3:59:47 PM EDT
13.94
-0.92 (-6.19%)
4:22:15 PM EDT: $13.83 -0.11 (-0.79%)
Products, Regulatory

NRX Pharmaceuticals Announces Positive Results For Zyesami And Seeks U.S. Authorization To Treat Critical COVID-19

Published: 06/01/2021 11:03 GMT
NRX Pharmaceuticals Inc (NRXP) - Nrx Pharmaceuticals Announces Positive Results for Zyesami™ (aviptadil-acetate) and Submits Emergency Use Authorization Application to US Food and Drug Administration to Treat Critical Covid-19 in Patients Suffering From Respiratory Failure.
Nrx Pharmaceuticals - Zyesami Showed a Significant Treatment Advantage in Patients Already Treated With All Approved Therapies for Critical Covid-19.
Nrx Pharmaceuticals - Zyesami Showed Shortened Hospitalization in Patients Already Treated With All Approved Therapies for Critical Covid-19.
Nrx Pharmaceuticals Inc - Full Data Results to Be Published in a Peer-reviewed Journal.